SBIR/STTR Research Award

Whole Blood Filter Paper Assay for Alzheimers Disease

Award identifier f4795530006c1250e24b620d50e0e3a061837b9f77fd22423b21fc28755d35ceAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$436,986

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Biospyder Technologies, Inc.
Proposal award date
2019-08-01
Contract end date
2021-01-31
UEI
KLCPP1J49GC5
Solicitation number
PAS18-187
Topic code
NIA

Research abstract

Summary In this Phase I program we will establish the feasibility of a novel filter paper whole blood sample based targeted sequencing assay based on the TempO Seqplatform to measure DNA and RNA profiles as the basis for the development of a minimally invasive prognostic diagnostic assay of Alzheimer s DiseaseADWe will use our already functional whole transcriptome targeted gene expression assay to evaluate a set of whole blood samples from AD and normal donors provided by our collaboratorsDrAllan LeveyDirectorAlzheimer s Disease ResCenter at Emory UnivChairDeptof Neurologyand DrAaron RitterCleveland ClinicLou Ruvo Center for Brain HealthWe will utilize the resulting data to define a smaller targeted AD specific gene subsetthen redesign the probes for those genes to be compatible with the TempO Seq DNA assayThis will allow us to generate a combined DNA RNA assay capable of detecting both critical DNA genotypese gAPOE allelesand the diagnostic prognostic gene expression RNA profile from dried blood spot samplesall in a single welladdition only assaywith no extractionreverse transcriptionor wash stepsFinallywe will combine the assay with a fill in elementallowing mapping of significant stretches of genes which can harbor multiple unpredictable mutationssuch as PSENor APPto create aone shotassay capable of detecting all relevant genetic and transcriptomic biomarkers in one single stepall from smallmmareas of blood spots on filter paperThe functionality of the completed assay will be confirmed on the same set of normal AD samplesallowing us to proceed to Phase IIwhere we will commercialize the assay and prove its predictive and diagnostic valueThis novel assay will address the unmet need for a cost effectivesimple way to broadly screen at risk populationsespecially in hard to reach or otherwise underserved areasAbility to derive data of such unprecedented depth from samples that are as non invasive and simple to collect and ship holds promise to reshape AD detection and careThe proposed research program is responsive to the NIA DBSR Special Interest Topic DtoDevelop multiple and reliable assays for limited blood spot specimens for large surveysand Division of Aging Biology Topic JDevelopment of biomarkers for prognosisdiagnosisor treatment monitoring of aging or aging related diseasesand DN Topic Adevelopment of minimally invasive biomarkers that can be used for screening in the general populationsbiomarkers that could serve as surrogate measures for disease progression in MCIAD and ADRDThe outcome will be an assay that can be taken into Phase II to begin the development and validation of a prognostic diagnostic screening assay for AD Narrative Blood spots collected on filter paper represent an easy to collecteasy to storeand easy to ship sample typebut one that also presents significant technical challenges for transcriptomicsas extraction from filter paper tends to produce low RNA yield and qualityHaving already developed a gene expression assay capable of detecting RNA levels directly on small samples of blood on filter paperwe now propose development of a targeted sequencing assay which is performed directly on the filter paper sample itselfand which will produce a full readout of gene expression biomarkers correlated with Alzheimer s Disease detection and progressionFurthermorewe propose combining this assay with a readout of relevant DNA genotypessuch ApoEor presenilin mutantsfor a fully one shotlow cost assay amenable to high throughput processing

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

26 SBIR/STTR records share this UEI (2013–2023). Reported award amounts total $19,935,581. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.